Table 3.
Laboratory parameters in patients after Fontan procedure and in controls.
| Variables | Fontan Group (n = 30) | Controls (n = 30) | p-Value |
|---|---|---|---|
| NT-proBNP, pg/mL | 148.0 (96.0–470.0) | 24.5 (6.0–35.0) | <0.001 |
| RBC, 109/μL | 5.5 (0.6) | 4.9 (0.5) | <0.001 |
| Hemoglobin, g/dL | 18.8 (1.8) | 14.7 (1.3) | 0.011 |
| Hematocrit, % | 47.6 (4.5) | 43.0 (3.3) | <0.001 |
| RDW, % | 13.2 (12.9–14.4) | 12.4 (12.0–12.6) | <0.001 |
| Platelet count, 103/μL | 164.4 (70.8) | 228.2 (38.1) | <0.001 |
| PDW, fL | 16.0 (3.2) | 12.2 (2.3) | <0.001 |
| MPV, fL | 12.0 (1.2) | 10.4 (1.0) | <0.001 |
| Cystatin C, mg/L | 0.9 (0.2) | 0.8 (0.1) | 0.009 |
| Creatinine, μmol/L | 72.8 (12.9) | 77.4 (14.2) | 0.19 |
| eGFR, mL/min/1.73 m2 | 116.5 (13.6) | 112.0 (12.9) | 0.26 |
| AST, IU/L | 24.0 (20.0–28.0) | 19.5 (17.0–22.0) | <0.001 |
| ALT, IU/L | 24.0 (19.0–27.0) | 20.0 (17.0–23.0) | 0.04 |
| GGTP, U/L | 61.5 (44.0–117.0) | 15.5 (14.0–18.0) | <0.001 |
| Bilirubin, μmol/L | 18.3 (10.7–34.0) | 12.0 (7.7–17.0) | 0.002 |
| α-Fetoprotein, ng/mL | 2.5 (1.9–3.6) | 2.3 (1.9–3.4) | 0.657 |
| ALP, U/L | 80.5 (64.0–88.0) | 67.0 (55.0–89.0) | 0.11 |
| Total protein, g/dL | 75.1 (70.2–78.8) | 75.0 (73.0–78.6) | 0.43 |
| Prothrombin time, s | 13.6 (12.6–15.2) | 11.9 (11.4–12.0) | <0.001 |
| INR | 1.2 (1.2–1.65) | 1.0 (0.9–1.1) | <0.001 |
| AST/ALT ratio | 1.1 (0.4) | 1.0 (0.3) | 0.21 |
Continuous data are presented as mean (SD) or median (Q1–Q3). Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AST/ALT ratio, ratio of aspartate transaminase to alanine transaminase; eGFR, estimated glomerular filtration rate; GGTP, γ-glutamyl transpeptidase; INR, international normalized ratio; MPV, mean platelet volume; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PDW, platelet distribution width; RBC, red blood cells; RDW, red cell distribution width.